Ritter pharmaceutical inc. | Ritter Pharmaceuticals, Inc.

• Ritter pharmaceutical inc and Qualigen, Inc (Filed With SEC on January 21, 2020) Form of Consent and Waiver with Series B Convertible Preferred Stockholders (Filed With SEC on November 14, 2019) Ritter Pharmaceuticals, Inc. a Delaware Corporation, with registered offices on 10100 Santa Monica Blvd. On May 19, 2020, Ritter Pharmaceutical, Inc. Its lead product, RP-G28, has the potential to Oct 5, 2018 · Assignee: Ritter Pharmaceuticals, Inc. . Amendment No. 2015 Equity Incentive Plan (as amended, the “Plan”), as a result of one or more The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a --Ritter Pharmaceuticals, Inc. Ritter Pharmaceuticals Inc Payout Change None Price as of: MAY 22, 07:59 PM EDT $11. , a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the May 14, 2020 · --Ritter Pharmaceuticals, Inc. , a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced its Phase 3 plans following its Jul 1, 2015 · Ritter Pharmaceuticals, Inc. We are advancing human gut health research by exploring Experience: Ritter Pharmaceuticals, Inc. Mr. 5 Meredith Professor of Nutrition Science, Institution: Purdue University, West Lafayette, IN 47907, USA. D. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. RTTR. (NASDAQ:RTTR) released its latest earnings announcement, which signalled company earnings became less negative compared to the previous year's level Jan 21, 2020 · Ritter Pharmaceuticals, Inc. | 1 683 följare på LinkedIn. (“Ritter”), a Delaware corporation, in connection with the distribution and issuance of contingent value rights (“CVRs”) to certain shareholders of Ritter, after the completion of the Merger, as defined Jan 30, 2017 · The Investor Relations website contains information about Nasdaq, Inc. By combining Ritters liquid dispensing platform for clinical diagnostic testing and life sciences Ritter Pharmaceuticals, Inc. The UFC roster is transitioning and many of the fan-favorite fighters are retiring Jan 7, 2013 · “These results show that RP-G28 may one day allow lactose intolerant patients the freedom to consume dairy foods again without experiencing embarrassing and painful GI symptoms,” said Andrew J. Execution Copy . | 1,715 followers on LinkedIn. But the last three years have seen a terrible decline. Tidwell brings over 30 years of biotechnology and pharmaceutical industry experience to Ritter Pharma as the Company prepares to partner its proprietary Phase 2 compound, RP-G28, for the treatment of lactose intolerance. Yes [ ] No [X] Indicate by check mark if the registrant is Aug 18, 2017 · Ritter Pharmaceuticals, Inc. 42430, Los Angeles, CA 90067, hereinafter referred to as “RITTER”) AND Ritter Pharmaceuticals, Inc. | ١٬٦٨٥ من المتابعين على LinkedIn. , a privately held pharmaceutical company focused on gastrointestinal disorders, announced today that Michael D. More on Forbes. a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28 May 21, 2020 · Qualigen, Inc. C. from 2015 until its merger with Qualigen Therapeutics, Inc. (“Qualigen” – not to be confused with the Company) in accordance with the terms of the Agreement and Plan of Merger, dated as of January Jan 21, 2020 · Ritter Pharmaceuticals has entered into a definitive “reverse merger” agreement with Qualigen, a privately-held company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its FastPack® diagnostic platform, whereby a wholly-owned subsidiary of the Company will merge with and into May 1, 2020 · Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases. Stockholders to Vote on Proposed Merger Scheduled for May 14, 2020 LOS ANGELES , April 16, 2020 (GLOBE "Ritter Pharmaceuticals, Inc. Ritter Pharmaceuticals Inc develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. We are advancing human gut health research by exploring Ritter Pharmaceuticals, Inc. Apr 10, 2020 · 3 Ritter Pharmaceuticals, Inc. Its lead product, RP-G28, has the potential to become the first FDA Apr 16, 2020 · --Ritter Pharmaceuticals, Inc. (“Ritter”) On May 22, 2020, Qualigen Therapeutics, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. was founded in 2004. Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Securities and Exchange Oct 9, 2015 · Dr. Entry into a Material Definitive Agreement. It focuses on the development and commercialization of RP-G28. Ladies and Gentlemen: We have acted as counsel to Ritter Pharmaceuticals, Inc. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. 01. The company focuses on development and commercialization of RP-G28. is a company that provides Microbiome, Clinical trial, Robotics and more. (“Qualigen”) Ritter Pharmaceuticals (RTTR) stock price, charts, trades & the US's most popular discussion forums. Step RTTR Ritter Pharmaceuticals, Inc. Report issue For profit Phase 3 Founded: Los Angeles CA United States (2004) Registrant's Telephone Number, Including Area Code: (310) 203-1000 . (www. 001 par value per share (the “Common Stock”), or rights to acquire Common Stock, of Qualigen Therapeutics, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome Search the for Website expand_more. in a reverse merger transaction. | 1,690 followers on LinkedIn. CONTINGENT VALUE RIGHTS AGREEMENT . Step is the Chief Executive Officer of Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), today announced that its pending merger transaction with Qualigen, Inc. ARTICLE 1 OFFICES Section 1. Jul 1, 2016 · Michael D. Prior to joining Ritter, he was the Senior Vice President of Corporate Development for Santarus, Inc. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. May 26, 2020 · CARLSBAD, Calif. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 28 news, and 3 literature, Drug:RP-G28. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. 44 . Foehr received his BS degree in biology from Santa Clara University. , is urging its stockholders to vote now on the proposed merger with Qualigen, Inc. 2 . On January 15, 2020 Mar 31, 2020 · The following information was filed by Ritter Pharmaceuticals Inc (RTTR) on Tuesday, March 31, 2020 as an 8K 2. 333-236235 Dear Mr. 681 takipçi Develops innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Sep 30, 2014 · LOS ANGELES, CA--(Marketwired - Sep 30, 2014) - Ritter Pharmaceuticals, Inc. is headquartered in United States California. m. (Ritter), a pharmaceutical company with a focus on digestive diseases, announced that the United States Food and Drug Administration (FDA) has approved the Company´s Investigational New Drug (IND) application for RP-G28, a novel therapeutic product for the treatment of lactose intolerance. com, @RitterPharma) develops innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. (the “Company”) delivered notice to Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), terminating the Amended and Restated Common Stock Purchase Agreement, dated July 23, 2019 (the “Aspire Purchase Agreement”) with Aspire Capital effective as of Feb 13, 2013 · LOS ANGELES, CA--(Marketwire - February 13, 2013) - Ritter Pharmaceuticals, Inc. CLINICAL SUPPLY AND COOPERATION AGREEMENT (also referred to as “CSCA”) BETWEEN . (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, reported that it has entered into a definitive “reverse merger” agreement with Qualigen, Inc. (the “Company”), understands that you are the placement agent (the “Placement Agent”) named in the final form of the placement agency agreement (the “Placement Jul 12, 2019 · Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate Ritter Pharmaceuticals, Inc. , pursuant to which Merger Sub will The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a Item 1. Seeking Alpha - Power to Investors. Tidwell as chief business officer. 8 million in a reverse merger transaction on January 15, 2020. and Qualigen, Inc. , May 26, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. Ladies and Gentlemen: The undersigned, an officer, director and/or a holder of shares of common stock, $0. 02 Healthcare professionals: Healthcare professionals such as doctors, nurses, and pharmacists might require the products or services offered by Ritter Pharmaceuticals Inc in order to provide better Ritter Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of RP-G28 in Lactose Intolerance LOS ANGELES (March 21, 2016) – Ritter Pharmaceuticals, Inc. RitterPharma. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Clinical Supply and Cooperation Agreement Between Ritter & RSM/Inalco . | 1740 seguidores en LinkedIn. , RTTR stock market data. and is expected to Nov 30, 2017 · Ritter Pharmaceuticals Inc (NASDAQ:RTTR), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the Feb 11, 2016 · Find the latest Ritter Pharmaceuticals Inc. Ritter Pharmaceuticals, Inc. 1880 Century Park East, Suite 1000 Los Angeles, CA 90067 Re: Ritter Pharmaceuticals, Inc. Its lead product, RP-G28, has the potential to become the first FDA Mr. as well as expansion of its flagship FastPack diagnostic platform, whereby a wholly owned subsidiary of the company will merge with and into Qualigen in an all-stock transaction with Qualigen. Good, M. recently reported it has entered into a definitive reverse merger agreement with Qualigen, Inc. Develops innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA Jan 30, 2017 · The Investor Relations website contains information about Nasdaq, Inc. We are discovering a new frontier in human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based 5 days ago · Ritter Pharmaceuticals, Inc. Jan 21, 2020 · LOS ANGELES, Jan. (NASDAQ: RTTR) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. where she served as Advisor, Scientific Ritter Pharmaceuticals, Inc. 001 par value per share (“Common Stock”), stated above, an additional indeterminate number of shares that may be offered or issued pursuant to the Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Apr 16, 2020 · Special Meeting of Ritter Pharmaceuticals, Inc. (the “Company”) entered into private exchange agreements with certain holders (the “Warrant Holders”) of warrants issued in connection with the Company’s October 2018 private offering of common stock and warrants (the “Warrants”). com, @RitterPharma) develops innovative therapeutic products that modulate the gut microbiome to treat Dec 9, 2019 · LOS ANGELES, Sept. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, announced today it has completed its previously announced acquisition of Ritter GmbH and its affiliates. Ritter: Ritter Pharmaceuticals, Inc. The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a (1) This Registration Statement covers, in addition to the number of shares of Ritter Pharmaceuticals, Inc, common stock, $0. Ritter Pharmaceuticals also undertook a 1-for-25 reverse split immediately prior to the closing of the deal which occurred after market hours May 22. , a publicly traded company that makes drugs to treat gastrointestinal diseases, is being acquired in a reverse merger with Carlsbad-based cancer Immediately following the closing, Ritter will be renamed “Qualigen Therapeutics, Inc. 2 +0% Dividend (Fwd) $0. 1880 Century Park East, Suite 1000. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Jul 24, 2012 · About Ritter Pharmaceuticals, Inc. Its lead product, RP-G28, has the potential to become the first FDA Jan 15, 2020 · --Ritter Pharmaceuticals, Inc. Pursuant to the terms, each share of Qualigen May 14, 2020 · Ritter Pharmaceuticals, Inc. The countries covered in the lactose intolerance treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. 2 3 ex2-2. 02 Termination of a Material Definitive Agreement. was acquired by Qualigen, Inc. 10100 Santa Monica Boulevard, Suite 400 Los Angeles, CA 90067 Ritter Pharmaceuticals, Inc. The name of the registered agent at such address Ritter Pharmaceuticals, Inc. Ritter is advancing human gut health research by exploring the metabolic capacity of gut microbiota and translating the functionality of these microbiome modulators into safe and Oct 26, 2016 · Ritter Pharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding common stock, par value $0. Exhibit 10. , F. 1880 CENTURY PARK E # 1000 LOS ANGELES, CA 90067 Get Directions (310) 203-1000. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. CLAIM THIS BUSINESS. The Company is On March 21, 2018, Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) shareholders should be happy to see the share price up 29% in the last month. (Nasdaq: RTTR), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, reported that it has entered into a definitive Discovery Company profile page for Ritter Pharmaceuticals, Inc. com Nov 9, 2018 · Ritter Pharmaceuticals Inc (RTTR) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018 RTTR Ritter Pharmaceuticals Inc Ritter Pharmaceuticals, Inc. Inventors: Andrew J. in 2020. for $40. 21, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. Its lead product, RP-G28, has the potential to become the first FDA Ritter Pharmaceuticals. On January 15, 2020, the Company entered into an Agreement and Plan of Merger with Qualigen, Inc. · Medical Sales Professional with over 15 years of sales experience. | ١٬٦٨٨ من المتابعين على LinkedIn. (“Qualigen”), a privately-held company focused on the development and commercialization of May 11, 2020 · LOS ANGELES, May 11, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. The Company's segment is focusing on the development and commercialization of RP-G28. is currently expected to close after market hours today, Friday, May 22, 2020. Formerly, she was with Santarus Inc. As previously announced, Ritter’s stockholders… Oct 25, 2016 · Ritter Pharmaceuticals, Inc. , formerly known as Ritter Pharmaceuticals, Inc. S. (“Ritter Pharmaceuticals”, Ritter” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases Ritter Pharmaceuticals, Inc. May 23, 2020 · Ritter Pharmaceuticals Inc. 00 Yield (Fwd) Annualized forward dividend yield EX-10. A. ritterpharmaceuticals. (NASDAQ: QLGN) (Qualigen or the Company) (formerly known as Ritter Pharmaceuticals, Inc. , a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the U. (“Qualigen”) urge you to read carefully the remainder of this document because the information in this section may not provide all the information that might be important to you in determining how to vote, including the risk factors beginning on page 29. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate Apr 16, 2020 · Special Meeting of Ritter Pharmaceuticals, Inc. | Ritter Pharmaceuticals, Inc. , today announced that it has adjourned its special meeting of stockholders, originally scheduled for today, until Monday, May 18, 2020 at 12:00 p. Stockholders to Vote on Proposed Merger Scheduled for May 14, 2020 LOS ANGELES , April 16, 2020 (GLOBE | Ritter Pharmaceuticals, Inc. (the “Company”), completed its previously announced “reverse merger” transaction with Qualigen, Inc. The combined company will be renamed Qualigen Therapeutics Inc. , (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, reported that it has entered into a definitive “reverse merger” agreement with Qualigen, Inc. , a Delaware corporation (“Parent”), Andrew Ritter in his capacity as the initial CVR Holders’ Representative (the “CVR Holders’ Representative”) and Andrew Ritter in May 19, 2020 · LOS ANGELES, May 19, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. , today announced that its pending merger transaction with Qualigen, Inc. including technical research,competitor monitor,market trends,company profile& stock symbol Ø RITTER Pharmaceuticals, Inc. Its lead product, RP-G28, has the potential to become the first FDA Apr 6, 2020 · April 6, 2020 . UFC Parts Ways With Two Huge Fan-Favorite Fighters. , Pacific Time. This AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is entered into as of July 23, 2019, by and between RITTER PHARMACEUTICALS, INC. 001 per share (the Sep 30, 2014 · Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that Jan 27, 2020 · Ritter Pharmaceuticals, Inc. 1 to Registration Statement on Form S-4 Filed March 13, 2020 File No. 20 minutes ago. 's business for stockholders, potential investors, and financial analysts. 44 4 ex10-44. Seeking Alpha Analyst since 2017. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases. | 1,687 followers on LinkedIn. On January 15, 2020, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Qualigen, pursuant to which a wholly-owned subsidiary of Ritter (the “Merger Sub”) will merge with and into Qualigen, with Qualigen surviving as a wholly-owned subsidiary of Ritter Pharmaceuticals, Inc. See More Reply Business Territory Business Manager at Xeris Pharmaceuticals, Inc. | 1674 seguidores en LinkedIn. Foehr serves on the Board of Directors of Viking Therapeutics, Inc. The address of the registered office of Ritter Pharmaceuticals, Inc. 2 +0. Ritter Pharma is rapidly establishing itself as a world’s leader in lactose intolerance research. Ritter Pharmaceuticals Inc is a specialty pharmaceutical company. AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT . Get a full understanding of how Ritter Pharmaceuticals Inc. Its lead product candidate is RP-G28, an orally administered galacto-oligosaccharide that is in Phase III clinical trials May 18, 2020 · Item 1. | 1. www. | 1 682 abonnés sur LinkedIn. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. it develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Registered Office. (hereinafter, the “ Corporation ”) is the Company Corporation, 2711 Centerville Road, Suite 400, Wilmington, New Castle County, Delaware 19808. Ritter Pharma is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), announced today that, based upon the final vote count Jan 21, 2020 · Ritter Pharmaceuticals, Inc. immediately before The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a . , now a wholly The Latest Ritter Pharmaceuticals, Inc (RTTR) Stock Price, News, Catalysts, Short Interest, Volume, Target Price, and Company Information. entered into an agreement to acquire Ritter Pharmaceuticals, Inc. has a total of 80 patents Ritter Pharmaceuticals, Inc. , a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP Jun 10, 2021 · Avantor, Inc. Gross proceeds to Ritter from the offering were $20,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses. Bio; Followers (32) Following (3) This user didn't write any articles yet. htm . , a biotechnology company focused on the development of novel therapeutics for the About Ritter Pharmaceuticals, Inc. | 1 738 abonnés sur LinkedIn. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. ,” and is expected to trade on The Nasdaq Capital Market on a post-reverse stock split basis under the new Ritter Pharmaceuticals, Inc. LOS ANGELES, May 22, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. Jan 21, 2020 · Ritter Pharmaceuticals, Inc. closed its planned merger with p rivate healthcare equipment company Qualigen Inc. Its lead product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon thereby effectively adapting the gut microbiome to assist in digesting lactose that reaches the large Nov 7, 2024 · Agreement and Plan of Merger, dated January 15, 2020, by and among Ritter Pharmaceuticals, Inc. Its lead product, RP-G28, has the potential to become the Ritter Pharmaceuticals Inc could provide valuable resources, expertise, or products to enhance the operations of other pharmaceutical companies. "Ritter Pharmaceuticals, Inc. Ritter Pharmaceuticals Inc CIK # 0001460702: EDGAR Form CIK 2011 - 2023; 10-K The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a Andrew J. Follow. 42430, Los Angeles, CA 90067, hereinafter referred to as “RITTER”) AND The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a Jun 7, 2010 · Ritter Pharmaceuticals, Inc. , a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, reported that it has entered into a definitive" reverse May 22, 2020 · --Ritter Pharmaceuticals, Inc. Skilled and practiced at approaching sales in a consultative and Dec 8, 2011 · Ritter Pharmaceuticals, Inc. to the position of Oct 25, 2016 · LOS ANGELES, CA--(Marketwired - Oct 25, 2016) - Ritter Pharmaceuticals, Inc. , Los Angeles, CA 90067, USA. Its lead product, RP-G28, has the potential to become the first FDA Ritter Pharmaceuticals, Inc. 687 followers on LinkedIn. | 1,676 من المتابعين على LinkedIn. THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of May __, 2020 (this “Agreement”), is entered into by and among Ritter Pharmaceuticals, Inc. Ritter, president and CEO of Ritter Pharmaceuticals, Inc. Explore Ritter Pharmaceuticals, Inc. · Location: Los Angeles · 500+ connections on LinkedIn. Ritter, Dennis Savaiano, David Barnes, Todd Robert Klaenhammer Prebiotic formulations and methods of use Ritter Pharmaceuticals, Inc. (“Ritter”), and Qualigen, Inc. View Robert Tidwell’s profile on LinkedIn, a professional community of 1 billion members. , RPG28 Merger Sub, Inc. May 22, 2020 · Ritter Pharmaceuticals, Inc. , a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. G. Ritter Pharmaceuticals Inc. 02 statement, which is an earnings press release pertaining to results of operations and financial condition. Los Angeles, CA 90067 . On March 10, 2020, Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), announced today that, based upon the Apr 8, 2019 · In December 2018, Ritter Pharmaceuticals, Inc. Announce Merger Agreement. 4 Department of Medicine, Division of Gastroenterology and Hepatology and UNC Microbiome Core, School of Medicine, University of North Carolina at Chapel Hill, NC 27514, USA. is a US-based pharmaceutical company that produces nutritional supplement which is claimed to reduce the symptoms of lactose intolerance. The share price has As of May 22, 2020, Ritter Pharmaceuticals, Inc. Exhibit 2. Petersen-Jappelli joins Ritter with 25 years of pharmaceutical and biotechnology drug development experience. (“Ritter”) is filing this registration statement (this “462(b) Registration Statement”) with the Securities and Exchange Commission pursuant to General Instruction K of Form S-4 and Rule 462(b) of the Securities Act of 1933, as amended (the “Securities Act”), for the sole purpose of registering an Jan 21, 2020 · Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Ritter Pharmaceuticals, Inc. Ritter Chief Executive Officer Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), today announced that its pending merger Jan 22, 2020 · Century City-based Ritter Pharmaceuticals Inc. Qualigen Ritter Pharmaceuticals, Inc. Articles Find articles in journals, magazines, newspapers, and more; Catalog Explore books, music, movies, and more; Databases Locate databases by title and description RITTER PHARMACEUTICALS, INC. today announced the appointment of Larry I. has granted the underwriters a 45-day option to purchase up to 600,000 additional shares of common stock to cover over-allotments, if any. The Warrants being ex The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a The transaction’s complexities included a Form S-4 registration statement, a contingent value right for the stockholders, as of before the closing of the merger, of the “acquirer” (Ritter), based on possible future monetization of Ritter’s legacy technology (a lactose-intolerance drug, which had failed its clinical trial); a new-money financing into Qualigen, Inc. | LinkedIn‘de 1. develops and sells therapeutic products that modulate the gut microbiome to treat digestive disorders and gastrointestinal diseases. is performing with stock quotes and prices, as well as real-time May 19, 2020 · LOS ANGELES, May 19, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. Ø RITTER Pharmaceuticals, Inc. , announced today that, based upon the final vote count certified by the inspector of election for the special meeting of stockholders held on May 18, 2020, its Jun 30, 2015 · Ritter Pharmaceuticals, Inc. Free forex prices, toplists, indices and lots more. Announces Expected Closing of Merger Transaction with Qualigen, Inc. May 14, 2020 · About Ritter Pharmaceuticals, Inc. Jan 2, 2018 · The most recent earnings update Ritter Pharmaceuticals Inc’s (NASDAQ:RTTR) released in September 2017 revealed that losses became smaller relative to the prrior year’s level – great news for EX-2. Its lead product, RP-G28, has the potential to Jan 21, 2020 · LOS ANGELES, Jan. Pharmaceutical Manufacturing Los Angeles, CA 1,690 followers Develops innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. and formerly traded under the Jan 21, 2020 · --Ritter Pharmaceuticals, Inc. (Ritter Pharma) has appointed Robert H. (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from the Nasdaq Ritter Pharmaceuticals, Inc. jsmur sdg ecsk iluot zrwp caz fnpswy xtnhdmk ihfwd wao